SEC Filing Summary: Ventrus Biosciences, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Ventrus Biosciences, Inc. on January 27, 2011, covering events that occurred on January 25, 2011. The company is incorporated in Delaware and operates from New York, New York. Note: The request metadata references "Assembly Biosciences, Inc.," but the filing text explicitly identifies the registrant as "Ventrus Biosciences, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The filing reports significant changes to the Board of Directors and committee structure:
- Business Development Committee: Established on January 25, 2011, with Russell H. Ellison, Myron Z. Holubiak, and Thomas Rowland appointed as members.
- Committee Chair: Thomas Rowland was appointed as Chair of the Business Development Committee, tasked with pursuing business development for the company.
- Board Leadership Change: Russell H. Ellison was elected Chairman of the Board. This followed the immediate resignation of Thomas Rowland from the Chairman position.
- Employment Agreement: Dr. Ellison's appointment as Chairman is a term of his employment agreement, which became effective upon the company's initial public offering on December 22, 2010.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to reporting the specific governance events listed above.
Key Facts for Investor Verification
- Verify the distinction between the company name in the request metadata (Assembly Biosciences) and the actual registrant in the filing (Ventrus Biosciences).
- Confirm the effective date of Russell H. Ellison's employment agreement and his new role as Chairman of the Board.
- Review the composition of the newly formed Business Development Committee and the specific responsibilities assigned to Thomas Rowland as Chair.
- Check subsequent filings for financial data, as this 8-K contains no financial metrics.